Stanley Jordan, MD
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Stanley Jordan, MD sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Stanley Jordan, MD: 4 sponsored US clinical trials, none currently recruiting.
Stanley Jordan, MD sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is End Stage Renal Disease, with 2 trials.
Upper-quartile sponsor footprint
Stanley Jordan, MD sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
4 total, page 1 of 1
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
NCT03380962
Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant
NCT03380377
Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
NCT01178216
Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection
NCT01134510
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
How the Stanley Jordan, MD early-phase archive is shaped
4 indexed studies, none listed as recruiting (0% open); 3 completed (75%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: End Stage Renal Disease (2 trials), 6 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Stanley Jordan, MD: archived-pipeline peers nationwide
Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Stanley Jordan, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 archived trials
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Stanley Jordan, MD page
4 registered trials is a research-attention snapshot, not an endorsement of Stanley Jordan, MD or any single study.
- None of Stanley Jordan, MD's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- End Stage Renal Disease is the condition Stanley Jordan, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See End Stage Renal Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Stanley Jordan, MD pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.